Human umbilical cord mesenchymal stem cell three-dimensional culture source exosome as well as preparation method and application thereof

The three-dimensional culture of exosomes from human umbilical cord mesenchymal stem cells was solved, and the problems of oxidative stress and immune response in vitiligo were significantly enhanced by delivering specific miRNAs, and effective treatment of vitiligo was achieved.

CN119040259APending Publication Date: 2024-11-29FOURTH MILITARY MEDICAL UNIVERSITY
View PDF 12 Cites 0 Cited by

Patent Information

Application Number
CN202411468465.X
Authority / Receiving Office
CN · China
Patent Type
Applications(China)
Current Assignee / Owner
Filing Date
2024-10-21
Publication Date
2024-11-29

AI Technical Summary

Technical Problem

The prior art lacks effective antioxidant and immunosuppressive treatment methods to deal with oxidative stress and autoimmune response in vitiligo, resulting in poor treatment effects.

Method used

Exosomes from human umbilical cord mesenchymal stem cells were extracted by differential ultra-high-speed centrifugation, and their antioxidant, anti-apoptotic and immunosuppressive effects were used to transmit miR-132-3p and miR-125b-5p is used to enhance Treg cell-mediated immunosuppression and reduce melanocyte damage.

Benefits of technology

3D-Exos significantly improves skin pigment deletion in vitiligo mouse models, inhibits CD8+ T cells, expands and enhances the number and function of Tregs, has higher biological activity and therapeutic effects, and provides a new treatment for vitiligo. Strategy.

✦ Generated by Eureka AI based on patent content.

Smart Images

  • Figure HDA0005094055600000011
    Figure HDA0005094055600000011
  • Figure HDA0005094055600000012
    Figure HDA0005094055600000012
  • Figure HDA0005094055600000021
    Figure HDA0005094055600000021
Patent Text Reader

Abstract

The invention discloses a human umbilical cord mesenchymal stem cell three-dimensional culture source exosome as well as a preparation method and application thereof, and belongs to the technical field of stem cell repair and regeneration and immunoregulation. Comprising the following steps: (1) collecting umbilical cord-derived mesenchymal stem cells of newborns, and carrying out culture and passage; (2) performing three-dimensional culture on the subcultured mesenchymal stem cells; and (3) extracting the three-dimensionally cultured mesenchymal stem cell source exosome by a differential ultra-high-speed centrifugation method. The human umbilical cord mesenchymal stem cell three-dimensional culture source exosome provided by the invention shows better effects in the aspects of treating leucoderma and repairing skin injury, including more effective Treg cell mediated immunosuppression and melanocyte protection. According to the present invention, the miR-132-3p and the miR-125b-5p are transmitted by the 3D-Exos, such that the Treg cell mediated immunosuppression is enhanced while the skin melanocyte damage induced by the oxidative stress is reduced;
Need to check novelty before this filing date? Find Prior Art

Description

Technical Field

[0001] The present invention relates to the technical fields of stem cell repair and regeneration, anti-inflammation and immunomodulation, and in particular to exosomes derived from three-dimensional culture of human umbilical cord mesenchymal stem cells, and a preparation method and application thereof. Background Art

[0002] Autoimmune skin diseases are a type of skin disease caused by abnormal immune system reactions, characterized by the immune system mistakenly attacking its own skin cells or tissues, causing inflammation and damage. Such diseases include psoriasis, lupus erythematosus, vitiligo, scleroderma, dermatomyositis, and alopecia areata. With the deepening of medical research, scientists are actively developing new treatment strategies, such as stem cell therapy, gene therapy, and targeted therapy, aiming to provide patients with more effective and personalized treatment options. Vitiligo is a common depigmentation disease characterized by the destruction of epidermal and / or mucosal melanocytes. The global incidence rate is high and is increasing year by year. Due to the unknown pathogenesis of vitiligo and poor treatment efficacy, it has placed a heavy burden on patients' families and society. In recent years, our domestic and international peers have found that oxidative stress in vitiligo is the initial link in inducing melanocyte damage, and abnormal autoimmunity is the key factor leading to further destruction of melanocytes.

[0003] Currently, there is a lack of effective treatments that simultaneously provide antioxidant and immunosuppressive effects. Summary of the invention

[0004] The purpose of the present invention is to provide a human umbilical cord mesenchymal stem cell three-dimensional culture-derived exosomes and a preparation method and application thereof to solve the problems existing in the above-mentioned prior art. The present invention provides a new treatment for autoimmune skin diseases, taking vitiligo as an example. In particular, it is aimed at oxidative stress and autoimmune response, which are the two key links in the pathogenesis of vitiligo. And it was found through experiments that compared with traditional two-dimensional culture, exosomes (3D-Exos) derived from hUMSCs cultured in three dimensions have higher yields and stronger biological activities, including antioxidant, anti-apoptotic and immunosuppressive effects.

[0005] To achieve the above object, the present invention provides the following solutions:

[0006] One of the technical solutions of the present invention is a method for preparing exosomes derived from three-dimensional culture of human umbilical cord mesenchymal stem cells, comprising the following steps:

[0007] (1) Collecting mesenchymal stem cells from the umbilical cord of newborns, culturing and passage;

[0008] (2) Perform three-dimensional culture of subcultured mesenchymal stem cells;

[0009] (3) Differential ultracentrifugation was used to extract exosomes from mesenchymal stem cells cultured in three dimensions.

[0010] The second technical solution of the present invention is the exosomes derived from three-dimensional culture of human umbilical cord mesenchymal stem cells prepared by the preparation method.

[0011] The third technical solution of the present invention is the use of the exosomes derived from three-dimensional culture of human umbilical cord mesenchymal stem cells in the preparation of drugs for treating autoimmune skin diseases.

[0012] A fourth technical solution of the present invention is a drug for treating autoimmune skin diseases, comprising the exosomes derived from three-dimensional culture of human umbilical cord mesenchymal stem cells.

[0013] Based on the above technical solution, the present invention has the following technical effects:

[0014] The exosomes derived from three-dimensional culture of human umbilical cord mesenchymal stem cells provided by the present invention show better effects in the treatment of vitiligo, including more effective Treg cell-mediated immunosuppression and protection of melanocytes. 3D-Exos enhance Treg cell-mediated immunosuppression and reduce oxidative stress-induced melanocyte damage by delivering miR-132-3p and miR-125b-5p, providing a new treatment strategy for vitiligo. The use of 3D-Exos will be a promising treatment for vitiligo, providing a new strategy for skin oxidative damage repair and vitiligo treatment. BRIEF DESCRIPTION OF THE DRAWINGS

[0015] In order to more clearly illustrate the embodiments of the present invention or the technical solutions in the prior art, the drawings required for use in the embodiments will be briefly introduced below. Obviously, the drawings described below are only some embodiments of the present invention. For ordinary technicians in this field, other drawings can be obtained based on these drawings without paying creative work.

[0016] Figure 1 (A) is a schematic diagram of culturing hUMSCs under 2D and 3D conditions; (B) is an optical microscopy observation of hUMSCs cultured under 2D and 3D conditions; (C) is an optical microscopy showing that hUMSCs gradually form spheres over time under 3D culture conditions.

[0017] Figure 2(A) is a schematic diagram of the separation of exosomes from the supernatant of hUMSCs by ultracentrifugation; (B) is the observation of exosome morphology by transmission electron microscopy (TEM); (C, D) are the particle size distribution and statistical analysis of exosomes measured by nanoflow cytometry (n = 3 per group); (E) is the detection of exosome markers CD9, TSG101 and Alix by immunoblotting; (F) is the measurement of the polydispersity index (PDI) of 2D-Exos and 3D-Exos by ZetasizerNano-S90 (n = 3 per group). Statistical significance is expressed by t-test. ns indicates no statistical significance.

[0018] Figure 3 (A, B) Fluorescence microscopy was used to observe the uptake of PKH26-labeled 2D-Exos and 3D-Exos by PIG3V cells, and the mean fluorescence intensity was statistically evaluated (n = 5 per group); (C, D) Western blotting was used to analyze and quantify the expression of FetuinA and ICAM-1 proteins in the 2D-Exos and 3D-Exos groups. Statistical significance was expressed by t-test. * p<0.05, ** p<0.01, *** p<0.001; ns indicates no statistical significance.

[0019] Figure 4 (A) is the tail pictures and ImageJ analysis of mice in the PBS (n=3 or 4 mice per group), 2D-Exos (n=4 mice per group), and 3D-Exos (n=4 mice per group) groups at week 6 and week 15. (B) The percentage of tail pigmentation of the three groups of mice for 10 consecutive weeks (from week 6 to week 15) was calculated using Image J software (n=3 or 4 mice per group). (C) Immunofluorescence staining images showing CD8 in the epidermis of the tail of vitiligo mice through full-thickness staining + T cells (green) and melanocytes (red), as well as CD8 + The corresponding heatmaps of T cells (green) and melanocytes (red) (n = 3 or 4 per group). (D) is the immunofluorescence staining of CD8 + The lg values ​​of T / melanocyte numbers were used for statistical analysis. All sham group mice were treated with PBS only. Statistical significance was expressed by analysis of variance (ANOVA) and Tukey's test, respectively. * p<0.05, ** p<0.01, *** p<0.001.

[0020] Figure 5 (A, B) are flow cytometry and statistical analysis of the effects of PBS, 2D-Exos, and 3D-Exos on CD8+ Effects of PBS, 2D-Exos, and 3D-Exos on the proportion of T cells in mouse skin and blood (n = 3 or 4 per group); (C, D, E) Flow cytometry and statistical analysis of the effects of PBS, 2D-Exos, and 3D-Exos on the proportion of Treg cells in mouse skin and blood. Statistical significance was indicated by analysis of variance (ANOVA) and Tukey's test, respectively. * p<0.05, ** p<0.01, *** p<0.001, **** p<0.0001; ns indicates no statistical significance.

[0021] Figure 6 (A, B) are the effects of PBS, 2D-Exos and 3D-Exos on PBMCs and CD4 + The effects of 2D-Exos and 3D-Exos on the proportion of Treg cells were compared and quantitatively analyzed, and all groups were standardized to the PBS group (n = 6 per group). (C, D) CFSE-labeled Treg cells were co-cultured with 2D-Exos and 3D-Exos for 5 days, and the percentage of proliferating cells was evaluated by flow cytometry (n = 3 per group). (E) CD4 + T cells were co-cultured with 2D-Exos and 3D-Exos (the culture medium contained IL-2 and TGF-β), and after 5 days of stimulation with CD3 / CD28-activated magnetic beads, flow cytometry was used to detect changes in the proportion of Treg cells (n = 4 per group). (F, G) PBMCs were co-cultured with 2D-Exos and 3D-Exos, and after 48 hours of stimulation with CD3 / CD28-activated magnetic beads, flow cytometry was used to evaluate the percentage of IL-10 and TGF-β expression in Treg cells. All groups were standardized to the PBS group (n = 4 per group). Statistical significance was indicated by analysis of variance (ANOVA) and Tukey's test, respectively. * p<0.05, ** p<0.001, *** p<0.001, **** p<0.0001; ns indicates no statistical significance.

[0022] Figure 7 3D-Exos can restore Treg cells in the peripheral blood of vitiligo patients to suppress CD8 + T cell proliferation and activation ability. Among them, (A) is 3D-Exos and Treg cells and CD8 + Schematic diagram of T cell co-culture; (B, C) flow cytometry detection of 3D-Exos, Treg cells and CD8 + After co-culture of T cells, CD8 +Effects on T cell proliferation and activation; (D) After 3D-Exos and Treg cells were co-cultured for 48 hours, the medium containing 3D-Exos was removed and then co-cultured with CD8 + Schematic diagram of T cell co-culture; (E) Flow cytometry detection of 3D-Exos pre-treated Treg cells and CD8 + After co-culture of T cells, CD8 + Effects of T cell activation. Statistical significance was expressed by analysis of variance (ANOVA) and Tukey's test, respectively. * p<0.05; ns indicates no statistical significance.

[0023] Figure 8 (A, B) are the detection of intracellular ROS levels by immunofluorescence after using the fluorescent probe DHE (PE-Texas-Red) (n = 3 in each group); (C, D) are the detection of apoptotic (annexin V+ / PI-) and necrotic (annexin V+ / PI+) PIG3V cells by flow cytometry (n = 4 in each group). Statistical significance was indicated by analysis of variance (ANOVA) and Tukey's test, respectively. * p<0.05, ** p<0.01, *** p<0.001, **** p<0.0001.

[0024] Fig. 9 The expression differences of miR-132-3p, miR-125b-5p and miR-574-5p in exosomes under two-dimensional culture (2D) and three-dimensional culture (3D) conditions. Among them, (A) is a volcano plot showing the differentially expressed miRNAs between 2D-Exos and 3D-Exos; (B) is a heat map of differentially expressed miRNAs between 2D-Exos and 3D-Exos; (C) is RT-PCR analysis of candidate miRNA levels in 2D-Exos and 3D-Exos (n=3 in each group). Statistical significance was indicated by t-test, respectively. *** p<0.001; ns indicates no statistical significance.

[0025] Fig.10 3D-Exos exert antioxidant and immunosuppressive effects by delivering miR-125b-5p and miR-132-3p. Among them, (A, B) are flow cytometric analysis of the effects of different miRNAs overexpressed in 3D-Exos on the level of ROS in PIG3V cells (n=3 in each group); (C, D) are flow cytometric analysis of 3D-Exos NCOE or 3D-Exos 125OEEffects of 3D-Exos on apoptosis of PIG3V cells (n=3 in each group); (E) Evaluation of 3D-Exos by CCK8 kit NCOE or 3D-Exos 125OE Effects on cell activity (n=4 in each group); (F, G) Flow cytometry analysis of the effects of different miRNAs overexpressed in 3D-Exos on CD4 + Effect of Treg cells on T cells (n = 3 per group). Statistical significance was expressed by analysis of variance (ANOVA) and Tukey's test, respectively. * p<0.05, ** p<0.01, *** p<0.001, **** p<0.0001. ns indicates no statistical significance.

[0026] Fig.11 miR-125b-5p and miR-132-3p may exert their effects by targeting Bak1 and Sirt1 respectively. (A) is a schematic diagram of the binding site of miR-125b-5p and Bak1; (B) is a schematic diagram of the binding site of miR-132-3p and Sirt1; (C) is the result of the dual luciferase reporter gene experiment of miR-125b-5p and Bak1; (D) is the result of the dual luciferase reporter gene experiment of miR-132-3p and Sirt1. Statistical significance is indicated by t-test. **** p<0.0001, ns indicates no statistical significance.

[0027] Fig.12 RT-PCR detection of the efficiency of overexpression and knockdown of miR-132-3p and miR-125b-5p in hUMSCs. Among them, AC is RT-PCR detection of the efficiency of transfection of miR-132-3p, miR-125b-5p, and miR-574-5pmimic in hUMSCs; D and E are RT-PCR detection of the efficiency of transfection of miR-132-3p and miR-125b-5p inhibitor in hUMSCs; FH is RT-PCR detection of the expression of miR-132-3p, miR-125b-5p, and miR-574-5pmimic in the supernatant exosomes after transfection of hUMSCs; I and J are RT-PCR detection of the expression of miR-132-3p and miR-125b-5p inhibitor in the supernatant exosomes after transfection of hUMSCs. Statistical significance was indicated by t-test, ***p<0.001; ****p<0.0001, respectively. DETAILED DESCRIPTION

[0028] Various exemplary embodiments of the present invention will now be described in detail. This detailed description should not be considered as limiting the present invention, but should be understood as a more detailed description of certain aspects, features, and embodiments of the present invention.

[0029] It should be understood that the terms described in the present invention are only for describing special embodiments and are not intended to limit the present invention. In addition, for the numerical range in the present invention, it should be understood that each intermediate value between the upper and lower limits of the scope is also specifically disclosed. Each smaller range between the intermediate value in any stated value or stated range and any other stated value or intermediate value in the described range is also included in the present invention. The upper and lower limits of these smaller ranges can be independently included or excluded in the scope.

[0030] Unless otherwise indicated, all technical and scientific terms used herein have the same meanings as those generally understood by those skilled in the art. Although the present invention describes only preferred methods and materials, any methods and materials similar or equivalent to those described herein may also be used in the implementation or testing of the present invention. All documents mentioned in this specification are incorporated by reference to disclose and describe the methods and / or materials associated with the documents. In the event of a conflict with any incorporated document, the content of this specification shall prevail.

[0031] It will be apparent to those skilled in the art that various modifications and variations may be made to the specific embodiments of the present invention description without departing from the scope or spirit of the present invention. Other embodiments derived from the present invention description will be apparent to those skilled in the art. The present application description and examples are exemplary only.

[0032] The words “include,” “including,” “have,” “contain,” etc. used in this document are open-ended terms, meaning including but not limited to.

[0033] The technical solutions described in the present invention, unless otherwise specified, are all conventional solutions in the art, and the reagents or raw materials used, unless otherwise specified, are purchased from commercial channels or are publicly available.

[0034] The embodiment of the present invention provides a method for preparing exosomes derived from three-dimensional culture of human umbilical cord mesenchymal stem cells, comprising the following steps:

[0035] (1) Collecting mesenchymal stem cells from the umbilical cord of newborns, culturing and passage;

[0036] (2) Perform three-dimensional culture of subcultured mesenchymal stem cells;

[0037] (3) Differential ultracentrifugation was used to extract exosomes from mesenchymal stem cells cultured in three dimensions.

[0038] In some specific embodiments, the method for collecting mesenchymal stem cells from the neonatal umbilical cord includes: removing blood and vascular tissue from the neonatal umbilical cord, cutting it into pieces, and then culturing the tissue blocks adherently.

[0039] In some specific embodiments, the three-dimensional culture method comprises:

[0040] (1) When the cell fusion rate reaches 80%-90%, use 0.25% trypsin to digest the cells. When more than 90% of the cells appear wrinkled and rounded under the microscope, gently tap the cell bottle to make the cells fall off, thus terminating the trypsin digestion;

[0041] (2) Centrifugation, resuspend the cells in MSCBM medium, and inoculate 2 mL of the cell suspension into ultra-low adhesion six-well plates for three-dimensional culture.

[0042] In some specific embodiments, the centrifugation condition is 800 rpm for 5 min; and the MSCBM culture medium contains 0.1% penicillin / streptomycin and EliteGro factor.

[0043] In some specific embodiments, the cell concentration in the cell suspension is 2×10 5 / mL; the three-dimensional culture conditions include: 37°C, 5% CO2, 48h.

[0044] In some specific embodiments, the method for extracting exosomes derived from three-dimensionally cultured mesenchymal stem cells by differential ultrahigh-speed centrifugation includes: collecting supernatant derived from three-dimensionally cultured human umbilical cord mesenchymal stem cells, first 800g, 5min, 4°C, collecting the supernatant; 2000g, 30min, 4°C, collecting the supernatant; 20000g, 30min, 4°C, collecting the supernatant; 100000g, 120min, 4°C, discarding the supernatant; using 4°C pre-cooled sterile PBS to resuspend the precipitate at the bottom of the centrifuge tube; filtering the PBS resuspension with a 0.22μm filter; 100000g, 120min, 4°C, discarding the supernatant, and using 200μL, 4°C pre-cooled sterile PBS to resuspend to obtain the exosome suspension derived from three-dimensional culture of human umbilical cord mesenchymal stem cells.

[0045] The present invention establishes a three-dimensional culture system of hUMSCs by using an ultra-low adhesion culture plate, promotes spontaneous aggregation of cells to form multicellular spheres, and thus simulates a living environment that is more in line with the human body.

[0046] The embodiment of the present invention also provides exosomes derived from three-dimensional culture of human umbilical cord mesenchymal stem cells prepared by the preparation method.

[0047] The embodiment of the present invention also provides the use of the exosomes derived from the three-dimensional culture of human umbilical cord mesenchymal stem cells in the preparation of a drug for treating autoimmune skin diseases.

[0048] In some specific embodiments, the autoimmune skin disease comprises vitiligo.

[0049] An embodiment of the present invention further provides a medicine for treating autoimmune skin diseases, comprising the exosomes derived from three-dimensional culture of human umbilical cord mesenchymal stem cells.

[0050] In some specific embodiments, the drug is administered by systemic injection.

[0051] Example 1

[0052] 1. Extraction and three-dimensional culture of human umbilical cord mesenchymal stem cells

[0053] (1) Extraction of human umbilical cord mesenchymal stem cells: obtain a fresh, sterile, healthy umbilical cord of a newborn, remove any residual blood, immerse it in sterile PBS, and store it at 4°C. When separating, remove the umbilical cord, soak it in 75% alcohol for 3 minutes for disinfection, place the umbilical cord in sterile PBS (add penicillin / streptomycin at a ratio of 1:100), and use sterile ophthalmic scissors to cut it into small segments, each about 3-4 cm, and remove any residual blood. First, cut the vein (the one with the largest lumen visible to the naked eye), carefully remove the venous wall, and peel off the remaining tissues. Two arteries can be seen during the peeling process, and the arteries are discarded. After all tissues have been peeled off, cut them into pieces the size of rice grains. Spread the tissue in a culture bottle (75m 2 ) bottom, as evenly as possible, add 4mL culture medium to the cell bottle, place in the incubator for 4 hours to make the tissue close to the cell bottle (tissue side facing up); after 4 hours, put the cell bottle upright, keep the tissue surface moist, and add culture medium to 10mL after 2-3 days. About 2-3 weeks later, human umbilical cord mesenchymal stem cells basically grow out, adherent human umbilical cord mesenchymal stem cells are digested by trypsin and centrifuged, subcultured, and frozen in liquid nitrogen.

[0054] (2) Three-dimensional culture of human umbilical cord mesenchymal stem cells: When the cell fusion rate reaches 80%-90%, use 0.25% trypsin to digest the cells. Gently shake to allow the trypsin to fully contact the cells. Digest for about 30 seconds. When 90% of the cells appear to shrink and become round under the microscope, gently tap the cell bottle to make the cells fall off, and then terminate the trypsin digestion. Centrifuge at 800 rpm for 5 minutes and discard the supernatant. Add MSCBM culture medium (containing 0.1% penicillin / streptomycin and EliteGro factor) to resuspend the cells. The cell concentration is 2×10 5 / mL is appropriate, and each 2mL of cell suspension is inoculated into an ultra-low adhesion six-well plate, placed in a 37°C, 5% CO2 incubator for 48h, and the supernatant is collected to extract exosomes derived from three-dimensional cultured mesenchymal stem cells.

[0055] like Figure 1 As shown, the present invention successfully isolated hUMSCs from the umbilical cord Wharton's jelly of a healthy donor and demonstrated 2D and 3D culture systems. The 2D cultured hUMSCs were observed to be homogeneous spindle-shaped fibroblast-like cells by optical microscopy, while the 3D cultured hUMSCs spontaneously aggregated to form multicellular spheres after 48 hours of suspension culture.

[0056] 2. Exosome extraction steps

[0057] The supernatant from human umbilical cord mesenchymal stem cells (P3-P6) collected in two-dimensional culture and three-dimensional culture was used to obtain exosomes by differential ultracentrifugation. First, 800g, 5min, 4℃, pour out the supernatant to a new sterile centrifuge tube to collect the supernatant, discard the impurities at the bottom of the centrifuge tube, and remove the dead cells in the supernatant; 2000g, 30min, 4℃, pour out the supernatant to a new sterile centrifuge tube to collect the supernatant, discard the sediment at the bottom of the centrifuge tube, and remove the cell debris in the supernatant; 20000g, 30min, 4℃, pour out the supernatant to a new sterile centrifuge tube to collect the supernatant, discard the sediment at the bottom and wall of the centrifuge tube, Remove large vesicles from the supernatant; 100,000 g, 120 min, 4 ° C, discard the supernatant, and use 4 ° C pre-cooled sterile PBS to resuspend the sediment at the bottom of the centrifuge tube (exosomes); use a 0.22 μm filter to filter the PBS resuspension to remove impurities such as large vesicles; 100,000 g, 120 min, 4 ° C, discard the supernatant, and use 200 μL, 4 ° C pre-cooled sterile PBS to resuspend the exosomes; store the exosomes in a -80 ° C refrigerator for later use.

[0058] 3. Exosome identification

[0059] (1) Electron microscopic observation of the morphology of exosomes of human umbilical cord mesenchymal stem cells: 10 μL of exosomes were added dropwise on a copper grid and allowed to settle for 2 min. The floating liquid was removed with filter paper. 10 μL of uranyl acetate was added dropwise on the copper grid and allowed to settle for 1 min. The floating liquid was removed with filter paper. After drying at room temperature, the images were detected by electron microscopy at 100 kV.

[0060] (2) Nanoflow cytometry detection of exosome diameter of human umbilical cord mesenchymal stem cells: 10 μL of exosomes were taken, and the exosome sample was gradient diluted and loaded. After the exosome sample was tested, the particle size and concentration information of the exosomes could be obtained.

[0061] (3) Identification of exosome surface markers by immunoblotting: Take 100 μL of exosome solution to extract total protein, add 50 μL of RIPA lysis buffer, lyse on ice for 30 min, centrifuge at 12000 rpm for 20 min at 4°C, discard the precipitate at the bottom of the centrifuge tube, and transfer the remaining protein sample liquid to a new pre-cooled 1.5 mL EP tube. After mixing, take 5 μL of supernatant for protein quantification, and mix the remaining liquid with 5× loading buffer at a ratio of 4:1. After mixing, heat at 100°C in a metal thermostatic water bath for 10 min. After the protein cools, centrifuge it and freeze it in a -20°C refrigerator for later use. Use 10% SDS-PAGE gel plate for the following experiment, load 10μL exosome protein sample per well, perform electrophoresis, transfer membrane, block, dilute primary antibody to appropriate concentration with primary antibody diluent, antibody concentrations are CD9 (1:1000), Alix (1:2500), TSG101 (1:1000), FetuinA (1:1000), ICAM1 (1:1000). Incubate the membrane in an antibody incubation box at 4°C overnight, wash three times with TBST on a decolorizing shaker at room temperature to remove the antibody, each time for 15 minutes. Use TBST to prepare a secondary antibody working solution with 5% skim milk powder, add the corresponding secondary antibody, place the membrane on a shaker at room temperature to block for 1h, wash three times with TBST on a decolorizing shaker at room temperature to remove the antibody, each time for 15 minutes. Use an imager for exposure, development and image acquisition, and use Image Lab software for analysis.

[0062] like Figure 2 As shown, the present invention extracts exosomes from the supernatant of human mesenchymal stem cells by ultrahigh-speed centrifugation, and identifies the extracted exosomes by electron microscopy, nanoflow cytometry, and Western blot. The results show that the extracted exosomes are of good quality and high purity.

[0063] 4. Uptake of exosomes by vitiligo melanocytes PIG3V cells

[0064] To detect the uptake of exosomes by PIG3V cells, 2D-Exos and 3D-Exos were fluorescently labeled according to the manufacturer's instructions. Briefly, PKH26 dye working solution (100 μL, Umibio) was added to exosomes (100 μg). After 10 min of storage at room temperature, PBS was added for dilution. The labeled exosomes were ultracentrifuged at 100,000 × g for 120 min at 4 °C to remove excess dye from the labeled exosomes and resuspended in PBS. PKH26-labeled exosomes were co-cultured with PIG3V cells for 24 h, washed with PBS, fixed with 4% paraformaldehyde for 10 min, and permeabilized with 0.1% TritonX 100 for 10 min. Finally, F-actin was stained by incubation with Fluoro-488-conjugated Phalloidin (AATBioquest) for 90 min, and the nuclei were stained with Hoechst 33258 (Biyuntian Biotechnology). Then, the uptake of PKH26-labeled exosomes by PIG3V cells was observed by confocal laser scanning microscopy (Zeiss LSM 880). The fluorescence intensity of PKH26 was determined using image J software. PIG3V cells were cultured in DMEM / F12 medium, and PMA (10 ng mL -1 ,hyy-18739), CHO (200nmol·mL -1 ,Sigma), bFGF (10ng·mL -1 , Sino) and 5% fetal bovine serum (Gibico).

[0065] like Figure 3 As shown in the figure, compared with 2D-Exos, exosomes in the supernatant of 3D-cultured hUMSCs were more easily taken up by melanocytes. Further detection of exosome surface uptake-related proteins Fetuin A and ICAM-1 revealed that 3D-Exos expressed higher levels.

[0066] 5. Vitiligo mouse modeling and drug administration

[0067] Resuscitated B16F10 cells were cultured and expanded. When the cell density reached about 70%, the cells were collected by digestion and centrifugation, resuspended in 1 mL PBS, and counted. Each mouse was injected with 2×10 5cells, prepare the corresponding volume of cell suspension according to the number of mice to be injected + 2, keep the cells at 4°C throughout the process, and inject within 1 hour. The mice were selected from 6-8 week old C57BL / 6 female mice, and the hair in the injection area on the back was shaved clean before injection. Use an insulin needle to inject into the intradermal tissue at 15°. Then, CD4 antibody was injected intraperitoneally on the 4th and 10th day after the injection of B16F10 cells (10μg antibody per gram of mouse). On the 12th day, surgical scissors were used to remove the B16F10 tumor mass in the mouse epidermis, the tumor size was recorded, and the excised wound was nailed with steel nails. Mouse groups: Sham group: C57BL / 6 mice (no modeling) + PBS; PBS group: C57BL / 6 mice (vitiligo mice) + PBS; 2D-Exos group: C57BL / 6 mice (vitiligo mice) + 2D-Exos; 3D-Exos group: C57BL / 6 mice (vitiligo mice) + 3D-Exos; each group had 4-5 mice, and from the 30th day after intradermal injection of B16F10 cells, 50 μg / mouse of exosomes were injected into the tail vein once a week. After exosome administration for 10 weeks, subsequent experiments were performed.

[0068] 6. Macroscopic photography of the depigmentation of the tail of a vitiligo mouse

[0069] The mice were photographed at different times: before treatment, 5 weeks after treatment, and 10 weeks after treatment. ImageJ was used to analyze the depigmentation area of ​​the mouse tail, and the ratio of the sum of the white spots on the ventral and dorsal skin to the total area of ​​the mouse tail skin was the mouse depigmentation ratio.

[0070] like Figure 4 As shown, the effect of hUMSCs-Exos in treating vitiligo was evaluated by establishing a melanoma-Treg-induced vitiligo mouse model. Compared with 2D-Exos, 3D-Exos treatment significantly improved the depigmentation of vitiligo mice.

[0071] 7. Preparation, staining and flow cytometry analysis of single cell suspensions from mouse tail skin and peripheral blood

[0072] (1) Preparation of single cell suspension from mouse tail skin:

[0073] Collagenase was diluted to 1 mg / mL in 1640 medium, DNase was diluted to 2 mg / mL in FACS, and Dispase was diluted to 2.5 mg / mL in PBS. The tail of the vitiligo mouse was cut to about 4 cm in length, depilated and deboned, and placed in a 24-well plate. 1 mL of Dispase was added and incubated at 37°C for 30 min to separate the dermis and epidermis. The dermis was placed in the collagenase working solution and digested on a shaker at 37°C for 45 min. The skin fragments of the epidermis were then ground on a 70 μm filter and the single cell suspension was filtered into a 15 mL centrifuge tube. This operation was placed on ice. At the same time, the dermis was ground according to the same steps. Centrifuge at 4°C, 1300 rpm for 8 min, discard the supernatant, and resuspend in 400 μL FACS. Centrifuge again, discard the supernatant, and resuspend the cells in pre-cooled 100 μL PBS to obtain a single cell suspension of the skin. Label the flow tube, put the cell suspension into the flow tube, and proceed to the next experiment.

[0074] (2) Blood collection from vitiligo mice by removing eyeballs:

[0075] Grab the mouse by grabbing the mouse scalp and neck skin, and fix the tail with the little finger. Gently press the skin around the eye frame to be removed to make the eyeball congested and protruding. Use the forceps in the right hand to quickly clamp the eyeball, and use the prepared EDTA anticoagulant tube to collect the blood in the mouse eye socket. After the collection is completed, the mouse is killed by cervical dislocation. Add about 5 ml of 1× red blood cell lysis solution (ACK) to the blood, mix it with the blood and let it stand at room temperature for 5 minutes, add 2 times 1× PBS to dilute, and centrifuge at 1300rpm for 8 minutes. Repeat the steps of lysing red blood cells until the red blood cells are completely lysed, label the flow tube, and load the single cell suspension into the flow tube for the next experiment.

[0076] (3) Staining and flow cytometry analysis of single cell suspension

[0077] Add the antibodies corresponding to the corresponding surface antigens Mouse-CD4-PE, Mouse-CD4-FITC, Mouse-CD8-APC Cy7 1μL, Mouse-CD25-BV421 2μL to the labeled flow tubes, and incubate at 4℃ in the dark for 30min. Resuspend the cells with 2ml of PBS, and wash the unstained flow antibody dye at 1300rpm for 8min. Discard the supernatant and add 100μL of the newly prepared pre-cooled fixative (prepared according to the instructions, ready for use) to the flow tubes. Mix well and incubate at 4℃ in the dark for 30min. Add 2 ml of 1× permeabilization solution to resuspend the cells, wash at 1300 rpm for 8 min, discard the supernatant, add 1 ml of 1× permeabilization solution to resuspend the cells, mix thoroughly, incubate at 4°C in the dark for 30 min, add 1 ml of PBS to resuspend the cells, wash at 1300 rpm for 8 min; discard the supernatant, use pre-cooled 100 μL PBS to resuspend the cells, add 2 μL of the antibody Mouse-Foxp3-PE corresponding to the surface antigen to the labeled flow tubes, mix thoroughly, incubate at 4°C in the dark for 120 min. Add 2 ml of PBS to resuspend the cells, wash at 1300 rpm for 8 min to wash the unstained flow antibody dye. Discard the supernatant, resuspend in 400 μL FACS, and prepare for flow cytometry detection. In addition, use ZombieViolet Fixable Viability Kit (423113, biolgend) or 7AAD Vitality Staining Solution (420403, biolgend) according to the instructions to stain dead cells.

[0078] The results are as follows Figure 5 As shown, cells from mouse skin and peripheral blood were analyzed by flow cytometry, and 3D-Exos treatment significantly inhibited CD8 + T cell number, proportion and activated Treg cells.

[0079] 8. Construction, lentiviral production and cell transfection

[0080] Lentiviral vectors (GenePharma, Shanghai, China) were used to construct LV3-human-miR-125b-5p mimic vector, LV3-human-miR-132-3p mimic vector, LV3-human-miR-574-5p mimic vector (miROE), lv3-human-mir-125b-5p inhibitor vector, and LV3-human-miR-132-3p inhibitor vector (miRKD). Negative controls were constructed using LV3 empty lentivirus (miR-NCOE and miR-NCKD). When the cell density reached 40-50%, hUMSCs cultured in 24-well plates were infected with viruses according to the MOI value provided by the manufacturer. After cell proliferation, puromycin (1-4 μg / mL) was used for screening for 14 days. RT-PCR was used to verify the transfection effect.

[0081] The results are as follows Fig.12 As shown, the present invention adopts a lentivirus-based method to establish overexpression of miR-125b-5p, miR-132-3p and miR-574-5p (miR OE ), and knockdown of miR-125b-5p and miR-132-3p (miR KD ) hUMSCs, and the corresponding negative control (miR-NC OE and miR-NC KD ). Exosomes were then isolated from the conditioned medium of overexpression and knockdown hUMSCs and named 3D-Exos, respectively. NCOE 、3D-Exos 125OE 、3D-Exos 132OE 、3D-Exos 574OE 、3D-Exos NCKD 、3D-Exos 125KD and 3D-Exos 132KD Quantitative reverse transcription polymerase chain reaction (qRT-PCR) results confirmed that overexpression and knockdown of target miRNAs in hUMSCs were successfully established ( Fig.12 Subsequently, exosomes were isolated from their conditioned medium, and qRT-PCR results also confirmed the successful overexpression and knockdown of miRNAs in exosomes, which were then used in subsequent experiments ( Fig.12 (middle F~J).

[0082] 9. Flow cytometry to detect ROS levels in melanocytes

[0083] PIG3V cells in good culture status were used, and the cells were routinely digested with trypsin. After counting, they were inoculated on a confocal microplate (1×10 5 / dish) or six-well plate (1×105 / well), after 24 hours, the original culture medium was discarded, 1mL DMEM / F12 culture medium was added to each dish, different treatments were added according to different groups, and after 48 hours of culture, the experimental group cells were stimulated with 0.6mmol / LH2O2 for 24 hours, and then the original culture medium was removed, and the dishes were washed 3 times with 2ml PBS. 1ml of serum-free culture medium diluted PE-Teax Red ROS probe (Shanghai Beibo) was added to the control group and the experimental group, and the cells were incubated at 37℃ in the dark for 30 minutes, the serum-free culture medium containing the probe was discarded, and the dishes were washed 3 times with 2ml PBS to remove the unbound probes, and 1ml PBS was added to the dishes, and the intracellular ROS level was detected by confocal laser scanning microscopy or flow cytometry.

[0084] The results are as follows Figure 8 As shown, hUMSCs-Exos pretreatment reduced ROS levels in H2O2-treated PIG3V cells, and 3D-Exos had a better effect.

[0085] 10. Detection of melanocyte apoptosis by flow cytometry

[0086] PIG3V cells in good culture status were used, and the cells were routinely digested with trypsin. After counting, the cells were counted and the number of cells was calculated as 1×10 5 / well, the cells were inoculated in a 6-well plate, and the total volume of the culture medium in each well was 2 ml. After 24 hours, the original culture medium was discarded, and 2 ml of DMEM / F12 culture medium containing 5% fetal bovine serum was added to each well. Different treatments were added according to different groups. After 48 hours of culture, the cells in the experimental group were stimulated with 0.6 mmol / L H2O2. After 24 hours, the cell culture medium was aspirated into a centrifuge tube (containing the suspended apoptotic or necrotic cells), and the adherent cells were washed once with PBS. An appropriate amount of trypsin was added to digest the cells. Incubate at room temperature until the cells can be blown down by gentle blowing, and then neutralize to avoid insufficient or excessive trypsin digestion. Transfer to a tube containing the corresponding culture medium, centrifuge at 1000 rpm for 5 minutes, discard the supernatant, gently resuspend the cells with 1 ml PBS and count, and then centrifuge at 1000 rpm for 5 minutes to collect the cells. Wash the cells with PBS to remove the residual trypsin, add 400 μL 1× Binding Buffer to gently resuspend the cells, add 5 μL Annexin V-FITC, gently mix, incubate at room temperature in the dark for 15 minutes, add 10 μL PI staining solution, gently mix, and place on ice in the dark for 5 minutes. Perform flow cytometry within 30 minutes.

[0087] The results are as follows Figure 8 As shown in C and D, compared with 2D-Exos, 3D-Exos also significantly reduced PIG3V cell apoptosis, and the effect of 3D-Exos was better.

[0088] 11. PBMCs, CD4 + T cells and CD4 + Isolation and co-culture of T cells and hUMSCs-Exos

[0089] PBMCs were isolated from the peripheral blood of healthy donors and patients with vitiligo using Ficoll density gradient centrifugation. This invention was approved by the Medical Ethics Committee of the First Affiliated Hospital of the Fourth Military Medical University (approval number: KY20213331-1). MojoSort Human CD4 + T cell isolation kit to extract CD4 + T cells, using Naive CD4 + T Cell Isolation Kit II CD4 + T cells. These cells were suspended in RPMI 1640 containing 10% fetal bovine serum and 0.1% penicillin-streptomycin. Subsequently, PBMCs or CD4 + T cells (5×10 5 ) were transferred into 24-well plates and exposed to PBS, 2D-Exos (50 μg / mL), or 3D-Exos (50 μg / mL) for 3 days before flow cytometric analysis. + T cells (5×10 5 ) using different exosomes (3D-Exos NCOE ,3D-Exos 125OE ,3D-Exos 132OE ,3D-Exos 574OE ) at a concentration of 50 μg / mL for 3 days. Then, the cells were stimulated with CD3 / CD28 activating magnetic beads for 24 hours and analyzed using a BD LSRFortessa flow cytometer. CD4 + In the T cell differentiation experiment, cells (5×10 5 ) were co-cultured with 2D-Exos (50 μg / mL) or 3D-Exos (50 μg / mL) in RPMI 1640 medium supplemented with IL-2 (50 ng / mL), TGF-1 (10 ng / mL) and 10% fetal bovine serum. After 5 days of stimulation with CD3 / CD28 activated magnetic beads, the changes in the proportion of Treg cells were observed. In order to study the secretion of immunosuppressive effector molecules by Treg cells, PBMCs (5×10 5) were co-cultured with 2D-Exos (50 μg / mL) or 3D-Exos (50 μg / mL) in RPMI 1640 medium supplemented with 10% fetal bovine serum. The cells were then stimulated with CD3 / CD28 activation beads for 48 hours, with cocktail (containing BrefeldinA) for 6 hours, and then analyzed using a BD LSRFortessa flow cytometer. The cells were then stained with antibodies obtained from BioLegend: FITC anti-human CD4 (300506), BV605 anti-human CD25 (302632), APC anti-human CD25 (302610), BV421 anti-human Foxp3 (320124), PE anti-human Foxp3 (320008), PE-cy7 anti-human IL-10 (501420), APC anti-human TGF-0.05 (300006).

[0090] The results are as follows Figure 6 As shown, in vitro experiments verified that 3D-Exos treatment expanded the Treg cell population in the peripheral blood of healthy humans, which was achieved through Treg cell differentiation, and 3D-Exos also enhanced the function of Treg cells to secrete IL-10.

[0091] 12. Treg and CD8 + T cell co-culture and Treg cell proliferation assay

[0092] PBMCs were isolated from fresh blood samples of healthy controls and vitiligo patients using lymphocyte separation medium. + CD8 T cell isolation kit (Miltenyi Biotec) was used to extract CD8 from PBMC + T cells. Then use CD4 + CD25 + CD127 dim / - Tregs were isolated from PBMCs using the Regulatory T Cell Isolation Kit (Miltenyi Biotec) according to the manufacturer’s instructions. + In the T cell co-culture experiment, 3D-Exos (50 μg mL -1 ) for 48 hours. Then, pretreated or untreated Treg cells (2.5×10 4 Cells) were grouped with CD8 + T cell co-culture. CD8 + T cells were cultured in 96-well U-shaped plates containing RPMI 1640 medium supplemented with 10% serum, with 1×10 cells per well. 5 Cells, activated by CD3 / CD28 microbeads. CD8 +T cell proliferation assay was performed using CFSE (C34570, Invitrogen) staining according to the manufacturer's instructions and cultured for 5 days. + For T cell activation experiments, co-culture was performed for 24 h. For Treg cell proliferation experiments, Treg cells were stained with CFSE according to the above steps and co-cultured with 2D-Exos (50 μg / mL), 3D-Exos (50 μg / mL) and activated CD3 / CD28 microbeads for 5 days according to the experimental conditions. Cell proliferation was evaluated by flow cytometry based on CFSE signal (FACS Calibur, BD, NJ, USA). Cells were then stained with antibodies obtained from biolgend: FITC anti-human CD4 (300506), BV605 anti-human CD25 (302632), BV421 anti-human Foxp3 (320124), APC anti-human CD69 (310910).

[0093] The results are as follows Figure 7 As shown, 3D-Exos can restore the Treg cells in the peripheral blood of vitiligo patients to suppress CD8 + The ability of T cells to proliferate and activate.

[0094] 13. MiRNA library preparation and sequencing

[0095] MiRNA library preparation and sequencing of 2D-Exos and 3D-Exos were performed by Hangzhou Lianchuan Biotechnology Co., Ltd. Briefly, total RNA was extracted from exosomes (200 μg) purified from the supernatant of 2D-hUMSCs and 3D-hUMSCs, and both the 2D-Exos group and the 3D-Exos group contained 4 samples. The miRNA sequencing library was prepared using the TruSeq Small RNA Sample Preparation Kit (Illumina, San Diego, USA). After library preparation, the miRNA-seq library was sequenced on an Illumina Hiseq 2000 / 2500 using a 1×50 bp strand-specific protocol. The sequencing data can be accessed through the GEO series accession number GSE211008.

[0096] 14. Dual luciferase reporter gene assay

[0097] Bak1 and Sirt1 reporter vectors containing wild-type and mutant miR-125b-5p and miR-132-3p binding sites were constructed and then cloned into psiCHECKTM-2 Vector (Promega, Madison, WI, USA). 293T cells were seeded in 24-well plates and incubated for 24 hours before transfection. Next, luciferase vectors (0.5 μg) were co-transfected with the specified miRNA using lipofectamine 2000 (Invitrogen). After 48 hours of transfection, the luciferase activity of Renilla and firefly cells was measured using the dual-luciferase reporter assay system (Promega, Madison, WI, USA).

[0098] The results are as follows Fig. 9 As shown, high-throughput sequencing revealed differential expression of miR-132-3p, miR-125b-5p, and miR-574-5p in exosomes under two-dimensional culture (2D) and three-dimensional culture (3D) conditions.

[0099] Fig.10 It was shown that 3D-Exos exerted antioxidant and immunosuppressive effects by delivering miR-125b-5p and miR-132-3p. Fig.11 miR-125b-5p and miR-132-3p were shown to exert their effects by targeting Bak1 and Sirt1, respectively.

[0100] In summary, the present invention found that systemic administration of 3D-Exos can significantly improve skin depigmentation in vitiligo mouse models, as manifested by the reduction of white spots on the skin. 3D-Exos can reduce CD8 + The infiltration and function of T cells and the expansion of the number and function of Tregs in the skin and blood indicate its role in immune regulation. At the same time, the present invention also verifies that 3D-Exos promotes the differentiation of Treg cells and increases the secretion of immunosuppressive molecules in vitro. Moreover, 3D-Exos restores the inhibition of CD8 Treg cells in the peripheral blood of vitiligo patients. +T cell capacity. 3D-Exos has a significant inhibitory effect on H2O2-induced melanocyte apoptosis, indicating that it has anti-oxidative stress properties. The present invention also found through miRNA analysis and molecular experiments that miR-132-3p and miR-125b-5p enriched in 3D-Exos significantly promoted Treg cell-mediated immunosuppression and inhibited oxidative stress-induced melanocyte damage by targeting Sirt1 and Bak1, respectively. Compared with 2D-Exos, 3D-Exos showed better effects in the treatment of vitiligo, including more effective Treg cell-mediated immunosuppression and protection of melanocytes. 3D-Exos, by delivering miR-132-3p and miR-125b-5p, simultaneously enhanced Treg cell-mediated immunosuppression and inhibited oxidative stress-induced melanocyte damage, providing a new treatment strategy for vitiligo. The use of 3D-Exos will be a promising treatment for vitiligo with the potential for clinical application.

[0101] Obviously, the above embodiments of the present invention are merely examples for clearly explaining the present invention, and are not intended to limit the implementation methods of the present invention. For ordinary technical users in the relevant field, other different forms of changes or modifications can be made on the basis of the above description. It is not necessary and impossible to list all the implementation methods here. Any modifications, equivalent substitutions and improvements made within the spirit and principles of the present invention should be included in the protection scope of the claims of the present invention.

Claims

1. A method for preparing exosomes derived from three-dimensional culture of human umbilical cord mesenchymal stem cells, characterized in that: The following steps are involved: (1) Collecting mesenchymal stem cells from the umbilical cord of newborns, culturing and passage; (2) Perform three-dimensional culture of subcultured mesenchymal stem cells; (3) Differential ultracentrifugation was used to extract exosomes from mesenchymal stem cells cultured in three dimensions.

2. The preparation method according to claim 1, characterized in that: The method for collecting mesenchymal stem cells from the umbilical cord of a newborn comprises: removing blood and vascular tissue from the umbilical cord of the newborn, cutting it into pieces, and then culturing the tissue blocks adherently.

3. The preparation method according to claim 1, characterized in that: The three-dimensional culture method comprises: (1) When the cell fusion rate reaches 80%-90%, use 0.25% trypsin to digest the cells. When more than 90% of the cells appear wrinkled and rounded under the microscope, gently tap the cell bottle to make the cells fall off, thus terminating the trypsin digestion; (2) Centrifugation, resuspend the cells in MSCBM medium, and inoculate 2 mL of the cell suspension into ultra-low adhesion six-well plates for three-dimensional culture.

4. The preparation method according to claim 3, characterized in that: The centrifugation condition is 800 rpm for 5 min; the MSCBM culture medium contains 0.1% penicillin / streptomycin and EliteGro factor.

5. The preparation method according to claim 3, characterized in that: The cell concentration in the cell suspension is 2×10 5 / mL; the three-dimensional culture conditions include: 37°C, 5% CO2, 48h.

6. The preparation method according to claim 1, characterized in that: The method for extracting exosomes derived from three-dimensionally cultured mesenchymal stem cells by differential ultrahigh-speed centrifugation includes: collecting supernatant derived from three-dimensionally cultured human umbilical cord mesenchymal stem cells, first 800g, 5min, 4°C, collecting supernatant; 2000g, 30min, 4°C, collecting supernatant; 20000g, 30min, 4°C, collecting supernatant; 100000g, 120min, 4°C, discarding supernatant; resuspending the precipitate at the bottom of the centrifuge tube with sterile PBS precooled at 4°C; filtering the PBS resuspension with a 0.22μm filter; 100000g, 120min, 4°C, discarding supernatant, and resuspending with 200μL of sterile PBS precooled at 4°C to obtain the exosome suspension derived from three-dimensional culture of human umbilical cord mesenchymal stem cells.

7. Exosomes derived from three-dimensional culture of human umbilical cord mesenchymal stem cells prepared by the preparation method according to any one of claims 1 to 6.

8. Use of the exosomes derived from three-dimensional culture of human umbilical cord mesenchymal stem cells as claimed in claim 7 in the preparation of a drug for treating autoimmune skin diseases.

9. The use according to claim 8, characterized in that: The autoimmune skin diseases include vitiligo.

10. A drug for treating autoimmune skin diseases, characterized in that: Comprising the exosomes derived from three-dimensional culture of human umbilical cord mesenchymal stem cells as described in claim 7.

Citation Information

Patent Citations

  • Three-dimensionally cultured mesenchymal stem cells derived exosomes and preparation method and application thereof

    CN109913409A

  • Cell reprogramming method based on three-dimensional system

    CN110312788A

  • Anxa1 overexpressed umbilical cord mesenchymal stem cell exosome as well as preparation method and application thereof

    CN116083353A

  • Stem cell three-dimensional differentiation model and construction method and application thereof

    CN116333977A

  • Method for preparing exosome through low-oxygen culture of stem cells based on biological 3D printing

    CN116333978A